Please wait a minute...
J Zhejiang Univ (Med Sci)  2017, Vol. 46 Issue (2): 173-178    DOI: 10.3785/j.issn.1008-9292.2017.04.09
    
Expression and clinical significance of DNAJB11 in epithelial ovarian cancer
YAO Guorong1,3(),FU Yunfeng1,LI Yanli1,ZHOU Caiyun2,LV Weiguo1,*()
1. Department of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310006, China
2. Department of Pathology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310006, China
3. Department of Obstetrics and Gynecology, Huzhou Central Hospital, Huzhou, Zhejiang 313000, China
Download: HTML     PDF(3251KB)
Export: BibTeX | EndNote (RIS)      

Abstract  

Objective: To study the expression of DNAJB11 protein in epithelial ovarian cancer tissues and its clinical significance. Methods: Immunohistochemistry was used to examine DNAJB11 expressions in 105 tissue specimens of ovarian epithelial carcinoma, 23 normal ovarian tissues, 17 tissues of benign tumor, and 13 tissues of of borderline tumor. The correlations between protein expression and clinicopathological factors were analyzed by Chi square test.The correlations between protein expression and survival were analyzed by Kaplan-Meier and Cox regression. Results: Positive expression of DNAJB11 protein was observed in 0.0% in normal ovary and benign tumor, 7.69% in borderline tumor, and 78.10% in epithelial ovarian cancer, respectively. Positive expression of DNAJB11 protein was significantly higher than the rest of the ovarian tissues and normal ovarian tissues (P<0.001).Higher expression of DNAJB11 was more prevalent in tissues from patients with advanced FIGO stages, high serum CA125, poor histological differentiation, and serous cancer. Kaplan-Meier curves revealed that higher expression of DNAJB11 was significantly associated with poor disease-free survival and overall survival.Multivariate survival analysis revealed that strong positive expression of DNAJB11 was an independent prognostic factor for disease-free survival and overall survival. Conclusion: DNAJB11 may play a role in tumorigenesis and progression of epithelial ovarian cancer.Strong positive expression of DNAJB11 was an independent prognostic factor in epithelial ovarian cancer.



Key wordsOvarian neoplasms/pathology      Proteomics      Immunohistochemistry      Prognosis     
Received: 30 September 2016      Published: 31 October 2017
Corresponding Authors: LV Weiguo     E-mail: 110790470@qq.com;lbwg@zju.edu.cn
Cite this article:

YAO Guorong,FU Yunfeng,LI Yanli,ZHOU Caiyun,LV Weiguo. Expression and clinical significance of DNAJB11 in epithelial ovarian cancer. J Zhejiang Univ (Med Sci), 2017, 46(2): 173-178.

URL:

http://www.zjujournals.com/xueshu/med/10.3785/j.issn.1008-9292.2017.04.09     OR     http://www.zjujournals.com/xueshu/med/Y2017/V46/I2/173


卵巢上皮性癌组织中DNAJB11的表达及临床意义

目的:探讨DNAJB11蛋白在卵巢上皮性癌组织中表达及其临床价值。方法:采用免疫组织化学EnVision法检测105份卵巢上皮性癌的石蜡包埋组织DNAJB11蛋白的表达情况,并与23份正常卵巢组织、17份卵巢良性肿瘤组织、13份卵巢交界性肿瘤组织对比,用χ2检验分析其与临床病理特征的关系,用Kaplan-Meier法及COX比例风险回归模型分析其与患者生存预后的关系。结果:DNAJB11蛋白在正常卵巢组织及卵巢良性肿瘤中几乎不表达,在交界性肿瘤组织中阳性率为7.7%,在卵巢上皮性癌组织中阳性率为78.1%,卵巢上皮性癌组织中DNAJB11表达均高于其余各卵巢病变和正常卵巢组织(均P<0.01)。在细胞分化程度为G2~G3、临床分期为Ⅲ~Ⅳ期、组织学类型为浆液性、术前外周血CA125水平大于500 IU/L的卵巢上皮性癌患者中,卵巢上皮组织DNAJB11蛋白表达均高于细胞分化程度为G1、临床分期为Ⅰ~Ⅱ期、组织学类型为非浆液性癌和血CA125水平不超过500 IU/L的患者(均P<0.05)。Kaplan-Meier生存曲线显示,DNAJB11强阳性表达与上皮性卵巢癌患者的总生存预后及无瘤生存预后相关(P<0.01);多因素分析结果显示,DNAJB11蛋白强阳性表达是卵巢上皮性癌无瘤生存及总生存的独立预后因素。结论:DNAJB11蛋白可能在卵巢上皮性癌发生发展过程中起重要作用;卵巢上皮组织DNAJB11蛋白强阳性表达是卵巢上皮性癌患者的独立预后因素。


关键词: 卵巢肿瘤/病理学,  蛋白质组学,  免疫组织化学,  预后 
[n(%)]
组织类型 n 阴性 阳性 强阳性
正常卵巢组织 23 23 0(0) 0(0)
卵巢良性肿瘤 17 17 0(0) 0(0)
卵巢交界性肿瘤 13 12 1(7.7) 0(0)
卵巢上皮性癌 105 23 48(45.7) 34(32.4)
Tab 1 Comparison of DNAJB11 protein expression in different tissues of ovarian
Fig 1 The results of immunohistochemistry in epithelial ovarian tissues
特征 n 阴性 阳性 强阳性 χ2 P
 年龄(岁)
   ≤50 52 11 26 15 0.838 0.658
    > 50 53 12 22 19
 临床分期
   Ⅰ-Ⅱ 40 18 15 7 21.107 0.000
   Ⅲ-Ⅳ 65 5 33 27
 残余灶直径(cm)
   ≤1 75 20 32 23 3.489 0.175
    > 1 30 3 16 11
 细胞分化程度
   G1 14 7 5 2 7.808 0.020
   G2-3 91 16 43 32
 组织学类型
   浆液性 60 8 32 20 6.513 0.039
   非浆液性 45 15 16 14
 外周血CA125水平(IU/L)
   ≤500 60 18 27 15 6.559 0.038
    > 500 45 5 21 19
 化疗敏感性
   敏感 77 19 35 23 1.578 0.454
   耐药 28 4 13 11
Tab 2 Expression of DNAJB11 in epithelial ovarian cancer tissues and its relationship with clinical pathological features
Fig 2 Overall survival curves of patients with different DNAJB11 protein expressions of DNAJB11 protein in epithelial ovarian cancer tissues of patients
Fig 3 Tumor free survival curves of patients with different DNAJB11 protein expressions of DNAJB11 protein in epithelial ovarian cancer tissues of patients
因素 总生存 无瘤生存
HR(95% CI) P HR(95% CI) P
   年龄 1.582(0.875~2.861) 0.129 1.417(0.855~2.348) 0.176
   病理类型 1.037(0.547~1.967) 0.911 1.207(0.682~2.134) 0.519
   组织分化程度 1.453(0.403~5.234) 0.568 1.930(0.688~5.413) 0.211
   临床分期 3.515(1.470~8.404) 0.005 1.937(0.920~4.080) 0.082
   血CA125水平 1.345(0.669~2.702) 0.405 1.351(0.739~2.467) 0.328
   残余灶大小 1.116(0.571~2.181) 0.749 1.113(0.616~2.012) 0.723
   化疗疗程 1.011(0.509~2.007) 0.976 1.226(0.660~2.275) 0.519
   化疗敏感性 3.101(1.635~5.880) 0.001 2.245(1.266~3.982) 0.006
   DNAJB11阳性 1.035(0.357~2.998) 0.950 1.372(0.569~3.307) 0.482
   DNAJB11强阳性 2.168(1.059~4.439) 0.034 2.447(1.312~4.563) 0.005
Tab 3 Univariate survival analysis of COX in patients with ovarian cancer
因素 总生存 无瘤生存
HR(95% CI) P HR(95% CI) P
  临床分期 4.113(1.828~9.252) 0.001 2.560(1.321~4.960) 0.004
  化疗敏感性 3.454(1.966~6.068) <0.001 2.192(1.319~3.642) 0.002
  DNAJB11阳性 0.913(0.330~2.525) 0.861 1.333(0.573~3.101) 0.504
  DNAJB11强阳性 1.971(1.010~3.847) 0.047 2.259(1.244~4.102) 0.007
Tab 4 COX multivariate survival analysis of prognosis of patients with ovarian cancer
[1]   沈 铿 , 马 丁 . 妇产科学, 3版 北京 人民卫生出版社 2015, 321-
SHEN Keng , MA Ding . Obstetrics and Gynecology, 3rd Beijing People's Health Publishing House 2015, 321-
[2]   LI Y L , YE F , CHENG X D et al. Identification of glia maturation factor beta as an independent prognostic predictor for serous ovarian cancer[J]. Eur J Cancer, 2010, 46 (11): 2104- 2118
doi: 10.1016/j.ejca.2010.04.015
[3]   INNOCENZI D , ALò P L , BALZANI A et al. Fatty acid synthase expression in melanoma[J]. J Cutan Pathol, 2003, 30 (1): 23- 28
doi: 10.1034/j.1600-0560.2003.300104.x
[4]   BEREK J S , CRUM C , FRIEDLANDER M . Cancer of the ovary, fallopian tube and peritoneum[J]. Int J Gynecol Obstet, 2015, 131 (Suppl 2): S111- S122
[5]   YU M , HASLAM R H , HASLAM D B . HEDJ, an Hsp40 co-chaperone localized to the endoplasmic reticulum of human cells[J]. J Biol Chem, 2000, 275 (32): 24984- 24992
doi: 10.1074/jbc.M000739200
[6]   OHTSUKA K , HATA M . Mammalian HSP40/DNAJ homologs: cloning of novel cDNAs and a proposal for their classification and nomenclature[J]. Cell Stress Chaperones, 2000, 5 (2): 98- 112
doi: 10.1379/1466-1268(2000)005<0098:MHDHCO>2.0.CO;2
[7]   MASSEY S , BURRESS H , TAYLOR M et al. Structural and functional interactions between the cholera toxin A1 subunit and ERdj3/HEDJ, a chaperone of the endoplasmic reticulum[J]. Infect Immun, 2011, 79 (11): 4739- 4747
doi: 10.1128/IAI.05503-11
[8]   MARCINOWSKI M , H?LLER M , FEIGE M J et al. Substrate discrimination of the chaperone BiP by autonomous and cochaperone-regulated conformational transitions[J]. Nat Struct Mol Biol, 2011, 18 (2): 150- 158
doi: 10.1038/nsmb.1970
[9]   GUO F , SNAPP E L . ERdj3 regulates BiP occupancy in living cells[J]. J Cell Sci, 2013, 126 (Pt 6): 1429- 1439
[10]   JIN Y , AWAD W , PETROVA K et al. Regulated release of ERdj3 from unfolded proteins by BiP[J]. EMBO J, 2008, 27 (21): 2873- 2882
doi: 10.1038/emboj.2008.207
[11]   NAKANISHI K , KAMIGUCHI K , TORIGOE T et al. Localization and functionin endoplasmic reticulum stress tolerance of ERdj3, a new member of Hsp40 family protein[J]. Cell Stress Chaperones, 2004, 9 (3): 253- 264
doi: 10.1379/CSC-52.1
[12]   BERNAL-BAYARD J , CARDENAL-MU?OZ E , RAMOS-MORALES F . The salmonella type Ⅲ secretion effector, salmonella leucine-rich repeat protein (SlrP), targets the human chaperone ERdj3[J]. J Biol Chem, 2010, 285 (21): 16360- 16368
doi: 10.1074/jbc.M110.100669
[1] CAI Cheng,WANG Jianping,ZHONG Zhifeng,DAI Zhihui,WANG Qinghua,DONG Wuzhen,SHI Hongqi,LIU Qingwei,DU Jinlin. Hypoxia-inducible factor-1α and CD133 predicts pathological complete response and survival for locally advanced rectal cancer patients after neoadjuvant chemoradiotherapy[J]. J Zhejiang Univ (Med Sci), 2017, 46(1): 36-43.
[2] ZHENG Jiangjiang, ZHU Yin, LI Changshui, LI Yinya, NIE Qianqian, ZHU Ziling, DENG Hong. Expression of CD10 in tumor-associated fibroblast of cancerized or recurrent colorectal adenomas[J]. J Zhejiang Univ (Med Sci), 2016, 45(4): 335-341.
[3] YANG Suwen, WANG Wei, JIN Hong, ZHONG Yuhong, XIE Xinyou. Expression of microRNA-221/222 in patients with monoclonal gammopathy of undetermined significance and multiple myeloma[J]. J Zhejiang Univ (Med Sci), 2016, 45(4): 371-378.
[4] BIAN Wei, GUAN Jichao, XIE Xishao, TONG Jin, ZHANG Xiaohui, SHOU Zhangfei. Effects of interim hemodialysis on survival and clinical outcomes in patients with maintenance peritoneal dialysis[J]. J Zhejiang Univ (Med Sci), 2016, 45(2): 195-200.
[5] XU Fangying, LIU Qin, HAN Fengyan, XU Enping, LAI Maode, ZHAO Zhongsheng. Association of neuroendocrine differentiation with progression and prognosis of gastric adenocarcinoma[J]. J Zhejiang Univ (Med Sci), 2016, 45(1): 24-30.
[6] LAI Maode. Gastroenteropancreatic neuroendocrine neoplasms: concepts and related issues[J]. J Zhejiang Univ (Med Sci), 2016, 45(1): 5-9,23.
[7] YANG Wan-hua, WU Hai-ying, ZHANG Hong-ze, LIU Hong-xiang, WEI Yu-jie, SHI Bin. Prognostic value of Picco monitoring combined with plasma microRNA-150 detection in septic shock patients[J]. J Zhejiang Univ (Med Sci), 2015, 44(6): 659-664.
[8] YAN Shen-qiang, MAO Ying-ying, ZHONG Gen-long, ZHANG Sheng, LOU Min. Safety of intravenous thrombolysis in cerebral microbleeds patients with prior antiplatelet therapy[J]. J Zhejiang Univ (Med Sci), 2015, 44(6): 618-624.
[9] CHEN Zi-bo, CHANG Lin-lin, ZHOU Tian-yi, WANG Dan-dan, CHEN Ying, ZHAO Ping-ge, ZHU Hong. Sunitinib suppresses migration of ovarian cancer cells through negative modulation of TGF-β-mediated epithelial-mesenchymal transition[J]. J Zhejiang Univ (Med Sci), 2015, 44(5): 479-485.
[10] YANG Yan, LI Yu-mei, ZHANG Na, LI Wan-yun, OU Yu-rong, WANG Rui, ZHAO Fu-you, WU Qiong. Expression of gap junction protein connexin 26 in human hepatocellular carcinoma and its significance[J]. J Zhejiang Univ (Med Sci), 2015, 44(5): 517-524.
[11] WANG Ke, ZHAO Dong-qing, ZHANG Jian-jun, LI Yu-jian, ZHANG Hai-dong, SHEN Zhang-feng, HU Bin, WU Hai-bin. Risk factors of progressive brain contusion and relationship with outcome[J]. J Zhejiang Univ (Med Sci), 2015, 44(4): 410-416.
[12] YAN Wei, MOU Chao-hui, WU Sheng, LING Chen-han, WU Qun, HONG Yuan, CHEN Sheng, CAI Feng, ZHANG Jian-min, CHEN Gao. Pterional keyhole approach in surgical treatment of ruptured anterior circulation intracranial aneurysm: a report of 313 cases[J]. J Zhejiang Univ (Med Sci), 2015, 44(4): 366-370.
[13] LIN Kai-qing, ZHU Li-bo, ZHANG Xin-mei, LIN Jun. Role of mast cells in estrogen-mediated experimental endometriosis in rats[J]. J Zhejiang Univ (Med Sci), 2015, 44(3): 269-277.
[14] XI Xiao-ping, ZENG Ling-xia, Yu Fang-fang, LIU Hua-sheng. Effects of DNMT3A gene mutations on prognosis of patients with acute myeloid leukemia:a meta-analysis[J]. J Zhejiang Univ (Med Sci), 2015, 44(2): 197-203.
[15] LIU Xue-hong, ZHANG Yong, LIU Chuan-kang. Expression of neuron-specific enolase and synaptophysin in esophageal development of human embryos[J]. J Zhejiang Univ (Med Sci), 2015, 44(2): 184-188.